Hi stranger! Signing up for MypetMD is easy, free and puts the most relevant content at your fingertips.

Get Instant Access To

  • 24/7 alerts for pet-related recalls

  • Your own library of articles, blogs, and favorite pet names

  • Tools designed to keep your pets happy and healthy



or Connect with Facebook

By joining petMD, you agree to the Privacy Policy.


New Biospecifics Techonologies Injectable Collagenase Drugs Said to 'Dramatically Reduce' Canine Lipomas

ADVERTISEMENT
By Vladimir Negron    January 17, 2011 at 09:42AM / (0) comments

Biospecifics Technologies Corp., a biopharmaceutical company, announced the results of their Chien-802 clinical trial this month. Designed to evaluate the efficacy of injectable collagenase in canine lipoma, the trial showed "dramatic reductions" in the subcutaneous lipomas following the injections.

Canine lipomas are encapsulated fat deposits that occur under the skin, restricting motion and making the pet uncomfortable. According to a 1999 JAVMA report (1), lipomas occur in approximately 1.7 million dogs in the U.S. The only proven therapy for this condition is surgical excision of the lipoma, which involves the use of general anesthesia.

Biospecifics Technologies also announced in the release the initiation of a larger clinical trial, Chien-803, for the same indication. This trial will enroll 25 canines, each having two or more lipomas.
 

(1) Lund JAVMA Vol. 214, No. 9, May 1, 1999

Comments  0

Leave Comment


  • Lifetime Credits:
  • Today's Credits:
Hurry Before All Seats are Taken!
Enroll
Be an A++ Pet Parent! Take fun & free courses to earn badges & certifications. Choose a course»

ARCHIVES

 
MORE FROM PETMD.COM